Comparison of susceptibility of HIV-1 variants to antiretroviral drugs by genotypic and recombinant virus phenotypic analyses

•Phenotypic susceptibilities to six antiretroviral drugs were measured using a high-throughput, multi-cycle, recombinant virus phenotypic assay.•For most cases, the genotypic and in-house recombinant virus phenotypic analyses yielded similar results, with a concordance rate of 84.2%.•The cut-off intervals for HIV-1 antiretroviral drugs may be extended to some extent.•The disparity in HIV-1 susceptibility poses a need to invest the clinical outcome of antiretroviral therapy of special individuals.